Kymera Therapeutics

Test Release BusinessWire

*** This is a test sample for BUSINESS WIRE quarterly results release style. It will need to be removed before the site is set to live. *** Revenues of $4.7 billion Free cash flow of $0.6 billion GAAP diluted loss per share of $0.24 Non-GAAP diluted EPS of $0.78 Restructuring plan on-track to